64 studies found for:    daclatasvir
Show Display Options
Rank Status Study
1 Completed Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment
Condition: Hepatitis C
Intervention: Drug: Daclatasvir
2 Completed Drug Interaction Study With Darunavir/Ritonavir or Lopinavir/Ritonavir and Daclatasvir
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Darunavir;   Drug: Ritonavir;   Drug: Lopinavir/Ritonavir
3 Active, not recruiting A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir;   Drug: Daclatasvir;   Drug: Ribavirin
4 Active, not recruiting Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Condition: Hepatitis C Virus Genotype 4 Infection
Interventions: Drug: Asunaprevir;   Drug: Daclatasvir;   Drug: Ribavirin;   Drug: Pegylated Interferon alpha-2a
5 Active, not recruiting Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir
6 Withdrawn Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients
Condition: Hepatitis C
Interventions: Drug: Peginterferon alfa 2a;   Drug: Ribavirin;   Drug: Placebo matching Daclatasvir;   Drug: Daclatasvir
7 Active, not recruiting Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Pegylated interferon lambda (pegIFNλ);   Biological: Pegylated interferon alfa-2a (pegIFNα-2a);   Drug: Ribavirin;   Drug: Daclatasvir;   Drug: Placebo matching Daclatasvir
8 Completed Study of Daclatasvir and TMC435 for Subjects With Genotype 1 Chronic Hepatitis C
Condition: Hepatitis C Virus
Interventions: Drug: Daclatasvir (DCV);   Drug: TMC435;   Drug: Ribavirin;   Biological: pegIFNα-2a
9 Active, not recruiting Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
Condition: Hepatitis C
Interventions: Biological: Peginterferon Lambda-1a;   Biological: Peginterferon Alfa-2a;   Drug: Ribavirin;   Drug: Daclatasvir;   Drug: Telaprevir
10 Active, not recruiting UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C
Condition: Hepatitis C Virus Infection
Interventions: Drug: Daclatasvir;   Drug: Asunaprevir;   Drug: DCV 3DAA;   Other: Placebo for DCV 3DAA;   Other: Placebo for Daclatasvir;   Other: Placebo for Asunaprevir
11 Active, not recruiting Phase III HIV/HCV Co-Infection Daclatasvir (DCV)+ Sofosbuvir (SOF)
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir
12 Completed Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Condition: Hepatitis C
Interventions: Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: BMS-790052 (NS5A Inhibitor);   Drug: Ribavirin (RBV);   Drug: BMS-650032 (NS3 Protease Inhibitor);   Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a);   Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor);   Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor);   Drug: Placebo for Ribavirin (RBV)
13 Completed Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin
Condition: Hepatitis C
Interventions: Drug: Daclatasvir, Asunaprevir and BMS-791325 FDC;   Drug: BMS-791325;   Drug: Rosuvastatin
14 Terminated Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
Condition: Hepatitis C
Interventions: Drug: INX-08189;   Drug: Placebo matching with INX-08189;   Biological: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: Daclatasvir
15 Withdrawn Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C
Condition: Hepatitis C Virus
Interventions: Drug: Daclatasvir;   Drug: BMS-986094;   Drug: Ribavirin;   Drug: Placebo for BMS-986094
16 Completed Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor);   Drug: Placebo matching BMS-790052;   Drug: Pegylated-interferon alfa 2a;   Drug: Ribavirin
17 Active, not recruiting Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Subjects and Subjects Post-liver Transplant
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
18 Active, not recruiting A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
Condition: Hepatitis C Virus Infection
Interventions: Drug: Daclatasvir;   Drug: Asunaprevir;   Drug: Ribavirin;   Biological: pegIFNα-2b;   Drug: Telaprevir
19 Active, not recruiting Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Condition: Hepatitis C
Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
20 Active, not recruiting Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Condition: Hepatitis C Virus
Interventions: Drug: Daclatasvir;   Drug: Asunaprevir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years